Skip to the answer
CJC / guidebook

Questioning growth hormone offers

A hormone change is not a health result.

See who was studied, what was measured and why claims about sleep, muscle, fat loss or ageing go beyond the studies.

The misconception

Raising a hormone level proves the treatment improves health.

What the facts say

The research measured hormone changes. The studies reviewed as of September 28, 2026 did not measure the promised sleep, muscle, fat-loss or ageing benefits.

See the source notes

What the studies actually asked

Growth hormone is one of the body’s chemical signals, released by the pituitary gland. CJC-1295 is meant to make that gland release more of it.

The FDA, the Food and Drug Administration, counted 63 healthy adults across the published human research it reviewed.

Most received CJC-1295 only once.

The studies looked at hormone levels, how long CJC-1295 remained in the body, and other measured changes.

They did not test whether it improved sleep, reduced body fat, built muscle or slowed ageing.

The form matters to the evidence

DAC is an added chemical part that attaches to a protein in blood. It helps the form with DAC stay in the body for days.

The published human work appears to have used a form with DAC.

The FDA review found no human study of CJC-1295 without DAC.

A paper about one form does not fill the gap for another.

A clear glass lens resting beside folded blank paper on a dark green desk.
Look closely at the question a study asked.

What happened to the study that stopped early?

A study in patients was listed on ClinicalTrials.gov, the government’s public record of studies. That record says it stopped early, with no results posted as of September 28, 2026.

The FDA describes reports that a participant died of a heart attack and the study was then stopped. The treating doctor thought heart disease that had gone unnoticed was the likeliest explanation. These reports do not establish whether CJC-1295 caused the death or rule it out.

A study that ended early with no results cannot tell us whether the treatment helped.

Read a claim with a pencil in hand

  • Were the participants like me, or healthy volunteers?
  • Was this the same form being proposed?
  • Did the study measure my goal, or just a hormone level?
  • What did it find, and what is still missing?

As of September 28, 2026, the FDA review found no evidence that CJC-1295 treats growth hormone deficiency, a shortage of that hormone.

It also noted that approved treatments for that condition exist.

At a visit, ask what could be causing your symptoms. If a shortage of growth hormone is suspected, ask how to check for it and what approved treatments are available.

Open the evidence

The research records used here were checked September 28, 2026.

The journal link opens a short summary of one study. The FDA review brings together the few studies in people and explains which health benefits they did not measure.

Keep readingTurn the evidence gaps into visit questions